An Open-label, Randomised, Two-way Crossover Study, to Evaluate and Compare the Pharmacokinetics of Fluticasone Furoate, Administered From a Novel Dry Powder Device (Repeat Dose) and Intravenously (Single Dose), in Healthy Caucasian, Japanese, Korean and Chinese Subjects.
Latest Information Update: 20 Sep 2023
Price :
$35 *
At a glance
- Drugs Fluticasone furoate (Primary) ; Fluticasone furoate (Primary)
- Indications Asthma; Perennial allergic rhinitis; Rhinosinusitis; Seasonal allergic rhinitis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 12 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.